On August 10, JD HEALTH rose 3.03% in regular trading, trading at HK$40.1/share, with turnover of HK$52.0065 million.

On the news front, the company is scheduled to hold a board meeting on August 13 to review its unaudited interim results for the first half ending June 30 and discuss potential interim dividend distribution. Market expectations remain positive ahead of the earnings review. The company previously disclosed that it launched 65 new drugs in the first half, covering oncology, dermatology, and chronic disease segments, maintaining its industry-leading position in new drug launches for consecutive years.

Additionally, the company cancelled approximately 21.54 million repurchased shares on July 22, spending approximately HK$839 million at prices ranging from HK$32.05 to HK$45.17 per share, reducing total issued shares from approximately 3.211 billion to 3.190 billion — signaling management confidence in company valuation.

Within the Internet and Direct Marketing Retail sector, healthcare stocks broadly strengthened. Among peers, ALI HEALTH rose 3.21%, PA GOODDOCTOR rose 3.58%, BABA-W rose 2.02%, JD-SW rose 1.65%, and MEITUAN-W rose 1.08%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)